Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: This report is essential for prominent enterprises seeking fresh revenue opportunities, aiming to enhance their comprehension of the industry and its inherent dynamics. It provides valuable insights for firms interested in diversifying across various sectors or expanding their current activities into new geographical areas.

Rise in IBD Incidence to Boost the Demand of IBD Drugs Market

The global incidence and prevalence of Inflammatory Bowel Disease (IBD) are increasing, with marked variations between developed and developing nations. Crohn's disease and ulcerative colitis are more common in developed countries, potentially due to Western diets and lifestyle factors. Rapid urbanization has also contributed to the rise in autoimmune diseases, including IBD. While the incidence appears stable in the West, it is increasing in the developing countries, possibly due to Westernization and improved disease awareness. Recent studies show rising incidence rates, especially in regions with previously low rates. Europe has the highest incidence rates, followed by North America and Asia/Middle East. According to EFCCA (European Federation of Crohn´s and Ulcerative Colitis Associations) in 2022 there were 10 million people living with IBD worldwide. While according to CCFA ( Crohn’s & Colitis Foundation of America), as many as 70,000 new cases of IBD are diagnosed in the United States each year and estimated that approximately 80,000 children in the U.S. are affected with IBD. The IBD has reported to affect almost 1.6 million Americans, most of whom are diagnosed before the age of 35.

Genetic factors play a role, but changing incidence rates emphasize the significance of environmental factors. Socioeconomic shifts and the spread of Western lifestyle contribute to this rise. Extra intestinal manifestations and complications like colon cancer pose significant risks to patients, with long-term implications of treatment are still being understood. Gastroenterology clinics will face challenges managing both younger IBD patients and an aging population with comorbidities, necessitating careful management strategies.

Significant success in IBD Drug Development to Drive the Market Demand

Previously, the diagnosis rate of Inflammatory Bowel Disease (IBD) was low particularly impacting developing countries. Even in developed nations, diagnosing IBD was challenging, leading to prolonged misdiagnoses for many sufferers. However, recent improvements in diagnostics have expanded the patient pool, consequently driving demand for treatments and boosting market revenue.

There has been a rapid surge in randomized clinical trials for Crohn's disease (CD) and ulcerative colitis (UC) treatments, accompanied by detailed epidemiological studies. Despite initial debates, it's now evident that IBD predominantly affects individuals in industrialized nations, with its incidence on the rise. With the advent of newer technologies, there has been a paradigm shift reported in treatment of IBD. Some of the major recent developments include launch and approval of new drugs for instance:

In February 2024, Pfizer Inc. disclosed that the European Commission (EC) has approved marketing authorization for VELSIPITY (etrasimod) within the European Union for the management of moderately to severely active ulcerative colitis (UC) in patients aged 16 and above. This approval extends to individuals who have shown insufficient response, loss of response, or intolerance to conventional therapy or a biological agent.

In March 2024, Celltrion USA has introduced ZYMFENTRA (infliximab-dyyb), a subcutaneous (SC) version of infliximab, marking a significant advancement in treatment options. ZYMFENTRA stands as the sole subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.

In July 2023, the launch of Yuflyma (adalimumab-aaty) has been announced by Celltrion USA, presenting patients with a high-concentration (100mg/mL) and citrate-free formulation as an alternative option. Yuflyma is approved for the treatment of eight conditions, which encompass rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Additionally, Fiberoptic colonoscopy with biopsies and ileocolonoscopy have transformed the diagnosis of both UC and CD globally, particularly in defining disease extent and severity, consequently helping the patients to manage and control IBD.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Inflammatory Bowel Diseases Drugs market evolving?
• What is driving and restraining the Inflammatory Bowel Diseases Drugs market?
• How will each Inflammatory Bowel Diseases Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Inflammatory Bowel Diseases Drugs submarket develop from 2024 to 2034?
  
  What will be the main driver for the overall market from 2024 to 2034?


• Will leading Inflammatory Bowel Diseases Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Inflammatory Bowel Diseases Drugs projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Inflammatory
• Bowel Diseases Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Inflammatory Bowel Diseases Drugs market?
• Where is the Inflammatory Bowel Diseases Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Inflammatory Bowel Diseases Drugs market today, and over the next 10 years:

• Our 318-page report provides 112 tables and 192 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Inflammatory Bowel Diseases Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Inflammatory Bowel Diseases Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Indication Outlook

• Crohn's Disease
• Ulcerative Colitis

Route of Administration Outlook

• Oral
• Parenteral
• Rectal

Distribution Channel Outlook

• Hospital Pharmacy
• Retail Pharmacy
• E-commerce Pharmacy
• Others

Drug Class Outlook

• TNF-alpha Blockers
• Integrin Blockers
• Interleukin Inhibitors
• JAK Inhibitors
• S1Ps Modulators and Others

Drugs Outlook

• Cimzia
• Entyvio
• Humira
• Rinvoq
• Skyrizi
• Remicade
• Simponi
• Stelara
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• AbbVie
• Biogen
• Celltrion Healthcare Co.,Ltd.
• F. Hoffmann-La Roche Ltd
• Ferring B.V.
• Johnsons & Johnsons
• Novartis AG
• Pfizer
• Takeda Pharmaceutical Company Limited
• UCB S.A.

Overall world revenue for Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 in terms of value the market will surpass US$29.09 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 report help you?

In summary, our 310+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 Market, with forecasts for drugs, drug class, indication and route of administration each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 21 key national markets – See forecasts for the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.